MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-02255

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Tung Nadine, Zhao Fengmin, DeMichele Angela, Prat Aleix, Winer Eric P, Wright Jean L, Recht Abram, Weiss Anna C, Tjoe Judy A, Feldman Sheldon M, Rocque Gabrielle B, Smith Mary Lou, O'Sullivan Ciara C, Sardesai Sagar D, Tang Shou-Ching, Modi Shanu, Irvin William J, Unni Nisha, Battelli Chiara, Bagegni Nusayba, Krie Amy K, George Mridula A, Telli Melinda L, Borges Virginia F, D'Abreo Nina, Shah Payal, Villagrasa Patricia, Badve Sunil, Partridge Ann H, Miller Kathy D, Carey Lisa A, Wolff Antonio C

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point-3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)-will be reported when data mature.

METHODS

Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR.

RESULTS

A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER-]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER- and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER- tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables.

CONCLUSION

Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER- and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.

Для цитирования: Tung Nadine, Zhao Fengmin, DeMichele Angela, Prat Aleix, Winer Eric P, Wright Jean L, Recht Abram, Weiss Anna C, Tjoe Judy A, Feldman Sheldon M, Rocque Gabrielle B, Smith Mary Lou, O'Sullivan Ciara C, Sardesai Sagar D, Tang Shou-Ching, Modi Shanu, Irvin William J, Unni Nisha, Battelli Chiara, Bagegni Nusayba, Krie Amy K, George Mridula A, Telli Melinda L, Borges Virginia F, D'Abreo Nina, Shah Payal, Villagrasa Patricia, Badve Sunil, Partridge Ann H, Miller Kathy D, Carey Lisa A, Wolff Antonio C. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. DOI: 10.1200/jco-25-02255.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.